Anavex Life Sciences has recently announced promising outcomes from its phase 2b/3 trial of blarcamesine, marking a potential breakthrough in Alzheimer’s disease treatment. Blarcamesine, an investigational drug developed by Anavex, has demonstrated significant efficacy in reducing amyloid-ß biomarkers, a hallmark of Alzheimer’s pathology.   The trial involved 508 participants with early symptomatic Alzheimer’s disease, who […]